Coherus Oncology Inc (NASDAQ:CHRS) reported its fourth quarter and full-year 2025 financial results after the market close on March 9, 2026. The company’s key commercial asset, the PD-1 inhibitor LOQTORZI, continued its growth trajectory, but the financial figures presented a mixed picture against Wall Street expectations, leading to a negative after-hours market reaction.
Financial Performance Versus Estimates
The company's reported results for the fourth quarter of 2025 came in below analyst consensus estimates on the top line, while showing a narrower-than-expected loss on the bottom line.
- Revenue: Coherus reported Q4 net revenue of $12.7 million, falling short of the analyst consensus estimate of approximately $14.2 million. This miss was driven by total company revenue, though product revenue from LOQTORZI specifically grew to $12.4 million in the quarter.
- Earnings Per Share: The company reported a non-GAAP net loss per share of $0.34. This was slightly better than the estimated loss of $0.36 per share that analysts had projected.
For the full year 2025, LOQTORZI net revenue more than doubled to $40.8 million from $19.1 million in 2024, highlighting the drug's commercial ramp following its U.S. launch in January 2024.
Market Reaction and Strategic Context
Following the earnings release, shares of Coherus traded down over 6% in after-hours activity. This immediate negative reaction appears primarily tied to the revenue miss for the quarter. Investors are closely monitoring the commercial uptake of LOQTORZI as the cornerstone of Coherus’s pivot from a biosimilars company to an innovative oncology firm. While the EPS beat is a positive, the top-line shortfall may have raised questions about the near-term sales growth rate.
The market’s focus is likely split between the quarterly sales figure and the broader strategic and financial restructuring the company has undertaken.
Key Highlights from the Business Update
Beyond the quarterly numbers, the earnings report provided significant updates on Coherus’s operational and financial transformation:
- Debt Reduction: The company achieved a dramatic improvement in its balance sheet, reducing its secured and convertible debt by 90% from $480 million to $38.8 million over the 2024-2025 period.
- Strengthened Liquidity: Coherus ended the year with $172.1 million in cash, cash equivalents, and marketable securities, providing a runway to advance its pipeline. This position was bolstered by equity financings in October 2025 and February 2026.
- Pipeline Advancement: The company highlighted progress with its two key clinical candidates:
- Tagmokitug (anti-CCR8): Multiple Phase 1b/2a studies are underway in gastrointestinal cancers, head and neck cancer, and colorectal cancer, with initial data readouts expected throughout 2026. A combination study with Johnson & Johnson’s pasritamig in prostate cancer is anticipated in the second half of 2026.
- Casdozokitug (anti-IL-27): Enrollment is ongoing in a Phase 2 trial in first-line liver cancer, with a data readout expected in mid-2026. Previous data showed a 17% complete response rate.
- LOQTORZI Momentum: The company reported continued quarter-over-quarter and year-over-year growth for LOQTORZI, driven by new patient starts and longer treatment duration. It remains the only FDA-approved therapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) in the U.S.
Looking Ahead
Management did not provide specific financial guidance for 2026 in the release. However, the current analyst consensus estimates project the company’s full-year 2026 revenue to reach approximately $79.6 million, with an estimated loss per share of $0.98. For the first quarter of 2026, analysts are modeling revenue of around $17.3 million and a loss of $0.24 per share. The company’s ability to meet or exceed these future estimates will be critical for investor sentiment, as will clinical data readouts from its pipeline expected this year.
For a detailed look at Coherus Oncology’s historical earnings and future analyst projections, you can review the earnings history and estimates and forecasts.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
